Author, year, title, journal	N=	Descri ption of subject s	Results	Pertinent discussi ons	Limitatio ns	Summar y
Li-Xin N, Li Y, Pan H, et al., 2011 Curcumi noids exert glucose- lowering effect in type 2 diabetes by decreasi ng serum free fatty acids, Molecula r Nutrition and Food Researc h	100	Overwe ight/ obese type 2 diabetic patients (BMI ≥ 24.0; fasting blood glucose ≥ 7.0 mmol/L) were separat ed into two groups in which n = 50 receive d a placebo and n= 50 receive d a 300mg supple ment of curcumi n per day for 3 months	Curcumin oids suppleme ntation significant ly decrease d fasting blood glucose (P < 0.01) and insulin resistanc e index (P < 0.01) in type 2 diabetic patients. Curcumin oids also led to a significant decrease in serum total FFAs (P < 0.001).	The findings of this paper suggest that there is a glucose-lowering effect of the active compone nts of turmeric, curcumin, in type 2 diabetes. These benefits can be contribute d to the effects this phytoche mical have on lowering serum FFA's levels.	The diets of these patients was not evaluate d or altered througho ut the study however, the consumption of different food compoun ds such as flavonoid s and other phytoche micals	After studying 100 overweig ht/ type 2 diabetic individual s who consume d either a placebo or 300 mg curcumin suppleme nt for 3 months, researche rs found that those who received a consistent suppleme ntation of curcumin had decrease d blood glucose levels, and improved insulin resistanc e.

Ghorban i Z, Hekmatd oost A, Parvin M., 2014 Ant- Hypergly cemic and Insulin Sensitiz er Effects of Turmeric and Its Principal Constitu ent Curcumi n, Internati onal Journal of Endocrin ology and Metaboli sm	240	Subject s who fell under the categor y of prediab etic were instruct ed to take three capsule s a day of either a placebo or curcumi n (250mg /day) for a total of 9 months	The curcumintreated group showed a better overall function of beta cells (P < 0.001) when compared with the placebo group.	Curcumin interventi on in prediabeti c populatio ns significant ly lowered the number of prediabeti c individual s who eventuall y develope d type 2 diabetes. The treatment appeared to improve overall function of beta cells, with very minor adverse effects.	The dosage given to patients typically isn't accessible or reasonable which may limit the use of this protocol for a typical prediabet ic patient.	After studying 240 prediabeti c patients it was found that when compared to a placebo treated group, those patients who received a curcumin suppleme nt for 9 months had better overall function of pancreati c beta cells.
Shehzad A, Gauh ar R, Lee Y; 2012 Curcumi n and Inflamm atory diseases . Journal of School of Life	Rev iew	Review; extensi ve researc h and observa tional studies.	Observati onal studies have shown that continuou s inflammat ion can activate the immune system	The findings of this paper reveal curcumin' benefits related to its anti-inflammat ory and antioxida nt properties	Although curcumin is a non-toxic nat ural anti-inflamma tory compoun d that has been already administ ered in phase II	According to data obtained in clinical trials and in vitro and in vivo researche s, the study is able to shows that

1 1				
Science s, BioFacto rs.	for long durations causing the progressi on of chronic diseases. Curcumin the active ingredient in turmeric has shown the capability to inhibit inflammat ory cell proliferati on, invasion, and angiogen esis. Also, evidence has shown inhibition of some enzymes that support and encourag e inflammat ion such as protein kinases, and cytokines	. Based of the available pharmaco logical data obtained from clinical trials, in vitro and in vivo research, an opportunit y exists to translate curcumin into clinics for the preventio n of inflammat ory diseases in the future.	and III clinical trials, additiona I human studies are required in order to validate the clinical use of curcumin for treating inflamma tory diseases.	curcumin may be associate d with the suppressi on of inflammat ory cytokines and enzymes. Also, transcripti on factors, some cells survival, invasion, and angiogen esis. Because curcumin has chemical properties that reduce inflammat ion, the occurrence of chronic diseases can be prevented by increasin g its consumpt ion.

The Efficacy of Turmeric and Inflammatory Diseases

Group Members: Nicolette Alfonso (5669196) Fiorella Anda (5130096) Jacob Demecillo (5155200) Sabrina Denis (3899098) Andreina Pinto (5973415)

Over the past few decades, spices available in plants and other sources of nature have been used as medicines for the prevention of inflammation. Turmeric (curcuma longa) and its' main active ingredient curcumin, have a long history of use as a treatment for inflammatory conditions in China and Southeast Asia. Numerous studies regarding turmeric have shown a great potential in reducing chronic inflammation due to its' strong anti-oxidation and anti-inflammatory activities. In vitro and invivo studies, especially clinical trials, indicate turmeric may be a potential therapeutic agent in treating diseases related to inflammation like obesity, diabetes, irritable bowel syndrome, and rheumatoid arthritis.

The prevalence of obesity continues to rise, therefore several studies on how curcumin may diminish possible complications have been conducted. Research demonstrates a direct interaction between curcumin and white adipose tissue, which suppresses chronic inflammation. The presence of dietary curcumin revealed stimulation of the expression of adiponectin, known as the most anti-inflammatory agent secreted by adipocytes, slowed body weight gain, and suppression of chronic low-grade inflammation. In a similar study closely observing lipid profile parameters, it was found that curcumin supplementation led to a significant reduction in serum triglyceride concentrations as well.